5-Aminosalicylates and colorectal cancer: Preventive role in chronic inflammatory bowel disease?;5-Aminosalicylés et cancer colorectal: Rôle prévertif au cours des maladies inflammatoires chroniques de l'intestin?

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 5, 2004, Pages 509-

  Desreumaux, Pierre ^a   Romano, Olivier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER PREVENTION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CROHN DISEASE; ENDOSCOPY; ENTERITIS; PROCTOCOLITIS; RISK REDUCTION;

EID: 3042587288     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(04)94978-0     Document Type: Short Survey

References (3)

1. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145-53.
2. Rubin DT, Djordjevic A, Huo D, Yadron N, Hanauer SB. Use of 5 ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis (abstract). Gastroenterology 2003;124:279.
3. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8.